 |
|
Identification of osteopontin as a urinary biomarker for autosomal dominant polycystic kidney disease progression
Hyunsuk Kim, Jinmo Sung, Ju Young Bae, Poongyeon Lee, Yun Kyu Oh, Hyunho Kim
Kidney Res Clin Pract. 2022;41(6):730-740. Published online 2022 Jun 20 DOI: https://doi.org/10.23876/j.krcp.21.303
|
|
Citations to this article as recorded by
 Rosuvastatin as a Supplemental Treatment for the Clinical Symptoms of Nephropathia Epidemica: A Pilot Clinical Study
Venera Shakirova, Maria Markelova, Yuriy Davidyuk, Robert J. Stott-Marshall, Toshana L. Foster, Svetlana Khaiboullina, Albert Rizvanov, Ekaterina Martynova
Viruses.2024; 16(2): 306. CrossRef Targeting integrin pathways: mechanisms and advances in therapy
Xiaocong Pang, Xu He, Zhiwei Qiu, Hanxu Zhang, Ran Xie, Zhiyan Liu, Yanlun Gu, Nan Zhao, Qian Xiang, Yimin Cui
Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef Osteopontin as a Biomarker in Chronic Kidney Disease
Satyesh K. Sinha, Michael Mellody, Maria Beatriz Carpio, Robert Damoiseaux, Susanne B. Nicholas
Biomedicines.2023; 11(5): 1356. CrossRef Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease—The Promised Land?
Camelia Pana, Alina Mihaela Stanigut, Bogdan Cimpineanu, Andreea Alexandru, Camer Salim, Alina Doina Nicoara, Periha Resit, Liliana Ana Tuta
Medicina.2023; 59(5): 915. CrossRef Factors Associated With the Development and Severity of Polycystic Liver in Patients With Autosomal Dominant Polycystic Kidney Disease
Yaerim Kim, Hayne Cho Park, Hyunjin Ryu, Yong Chul Kim, Curie Ahn, Kyu-Beck Lee, Yeong Hoon Kim, Seungyeup Han, Eun Hui Bae, Kyungjo Jeong, Jungmin Choi, Kook-Hwan Oh, Yun Kyu Oh
Journal of Korean Medical Science.2023;[Epub] CrossRef Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers
Iva Sorić Hosman, Andrea Cvitković Roić, Margareta Fištrek Prlić, Ivana Vuković Brinar, Lovro Lamot
Frontiers in Pediatrics.2023;[Epub] CrossRef
|